// App-Quantinova.ai

OP0124 (2021) : EFFECTS OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA-ILD) IN THE INBUILD TRIAL

Researchers

Presenter

  • C. Kelly

Principal Investigators

  • E. Matteson

  • M. Aringer

  • G. R. Burmester

  • H. Mueller

  • L. Moros

  • M. Kolb

Medical Centers

  • Newcastle University, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom

  • Mayo Clinic College of Medicine and Science, Division of Rheumatology, Rochester, United States of America

  • University Medical Center & Faculty of Medicine, TU Dresden, Rheumatology, Medicine III, Dresden, Germany

  • Charite Universitatsmedizin der HU-Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • McMaster University and St. Joseph’s Healthcare, Department of Medicine, Hamilton, Canada

Locations

  • United Kingdom

  • United States

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Glucocorticoid

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Oraprine

  • Cyclosporine eent

  • Nintedanib

  • Tacrolimus

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved